Superworth

Wave Life Sciences free cash flow WVE

Cash from operations less capital spending, by quarter and over the last twelve months, from 2014.

Last 12 months, to Jun 30, 2026
−$193.1M
Latest quarter, Q2 FY26
−$54.5M
Fiscal year 2025
−$188.2M

Wave Life Sciences' free cash flow was −$193.1M over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$54.5M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2025−$188.2Mn/a
FY2024−$152Mn/a
FY2023−$20.5Mn/a
FY2022−$129.1Mn/a
FY2021−$89.6Mn/a
FY2020−$117.3Mn/a
FY2019−$192.1Mn/a
FY2018−$32.8Mn/a
FY2017−$102.6Mn/a
FY2016−$37.4Mn/a
FY2015−$14.4Mn/a
FY2014n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q2 FY26−$54.5Mn/a−$193.1M
Q1 FY26−$60Mn/a−$185M
Q4 FY25−$33.8Mn/a−$188.2M
Q3 FY25−$44.9Mn/a−$198.2M
Q2 FY25−$46.3Mn/a−$200.1M
Q1 FY25−$63.2Mn/a−$181.3M
Q4 FY24−$43.7Mn/a−$152M
Q3 FY24−$46.9Mn/a−$141.8M
Q2 FY24−$27.5Mn/a−$129.6M
Q1 FY24−$33.8M−140%−$139.4M
Q4 FY23−$33.6Mn/a−$20.5M
Q3 FY23−$34.7Mn/a−$20.6M

Against its peers

Companies in Drug Manufacturers - General nearest Wave Life Sciences' size, closest first, today.

CompanyFree cash flow yield
WVEWave Life Sciences−30.8%
CRMDCorMedixn/m
ZVRAZevra Therapeutics5.6%
IRWDIronwood Pharmaceuticalsn/m
PBYIPuma Biotechnology7.2%
COLLCollegium Pharmaceuticaln/m
ARVNArvinas−43.7%
ABUSArbutus Biopharman/m
AMPHAmphastar Pharmaceuticals14.3%
OMEROmeros−5.7%
PCRXPacira BioSciences12.4%
Peer median6.4%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Wave Life Sciences

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.